Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Kreitman Website

Robert J. Kreitman, M.D.

Selected Publications

1)  Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.
High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.
Nat. Genet. 46: 8-10, 2014.
[Journal]
2)  Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
Clin. Cancer Res. 19: 6313-21, 2013.
[Journal]
3)  Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M.
Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Clin. Cancer Res. 19: 6873-81, 2013.
[Journal]
4)  Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM.
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
Leuk. Res. 37: 401-9, 2013.
[Journal]
5)  Kreitman RJ.
Hairy cell leukemia-new genes, new targets.
Curr Hematol Malig Rep. 8: 184-95, 2013.
[Journal]
6)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
[Journal]
7)  Tembhare PR, Marti G, Wiestner A, Degheidy H, Farooqui M, Kreitman RJ, Jasper GA, Yuan CM, Liewehr D, Venzon D, Stetler-Stevenson M.
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.
Am. J. Clin. Pathol. 140: 813-8, 2013.
[Journal]
8)  Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ.
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Blood. 119: 3330-2, 2012.
[Journal]
9)  Kreitman RJ.
Immunoconjugates and new molecular targets in hairy cell leukemia.
Hematology Am Soc Hematol Educ Program. 2012: 660-6, 2012.
[Journal]
10)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 2/19/2014.